Inclusion bias of patients with genetically different glioblastoma subgroups in clinical trials

Hartmann Christian

首页> 外文期刊>Neuro-Oncology >Inclusion bias of patients with genetically different glioblastoma subgroups in clinical trials

【24h】

Inclusion bias of patients with genetically different glioblastoma subgroups in clinical trials

机译：具有遗传差异的胶质母细胞瘤亚组患者的临床临床纳入偏倚

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Neuro-Oncology》 |2018年第10期|1285-1286|共2页
作者
Hartmann Christian;
展开▼
作者单位

Hannover Med Sch, Dept Neuropathol, Inst Pathol, Hannover, Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma [J] . Patel Daxa M., Foreman Paul M., Nabors L. Burt, Human gene therapy. Clinical development . 2016,第2期

机译：一期临床试验的设计，用于评估多发性/进展型胶质母细胞瘤，间变性星形胶质细胞瘤或胶质肉瘤患者中的M032（表达IL-12的基因工程HSV-1基因工程）
2. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. [J] . Monika E Hegi, Robert-Charles Janzer, Wanyu L Lambiv, Acta Neuropathologica . 2012,第6期

机译：新诊断的胶质母细胞瘤中存在少突胶质细胞瘤样成分，可确定病原学上异质的亚组，并且缺乏预后价值：EORTC_26981 / NCIC_CE.3试验的中心病理学评价。
3. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial [J] . Monika E. Hegi, Robert-Charles Janzer, Wanyu L. Lambiv, Acta Neuropathologica . 2012,第6期

机译：新诊断的胶质母细胞瘤中存在少突胶质细胞瘤样成分，可确定病原学上异质的亚组，并且缺乏预后价值：EORTC_26981 / NCIC_CE.3试验的主要病理学评价
4. Automatic Segregation and Classification of Inclusion and Exclusion Criteria of Clinical Trials to Improve Patient Eligibility Matching [C] . Tirthankar Dasgupta, Ishani Mondal, Abir Naskar, Health Intelligence Workshop;Association for the Advancement of Artificial Intelligence Annual Conference . 2020

机译：临床试验的自动分离与分类，改善患者资格匹配的临床试验
5. Patient motivation for participation in clinical trials for depression: Development and validation of the Motivation for Clinical Trials Inventory -Depression (MCTI-D) [D] . Loraas, Emily L. 2006

机译：参与抑郁症临床试验的患者动机：临床试验动机-抑郁症（MCTI-D）的开发和验证
6. Inclusion bias of patients with genetically different glioblastoma subgroups in clinical trials [O] . Christian Hartmann 2018

机译：具有遗传差异的胶质母细胞瘤亚组患者的临床临床纳入偏倚
7. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial [O] . Hegi, M E, Janzer, R C, Lambiv, W L, 2012

机译：新诊断的胶质母细胞瘤中存在少突胶质细胞瘤样成分，可确定病原学上异质的亚组，并且缺乏预后价值：EORTC_26981 / NCIC_CE.3试验的主要病理学评价
8. Inclusion of Minority Patients in Breast Cancer Clinical Trials: The Role of the Clinical Trial Environment [R] . Kaplan, C. P. 2010

机译：将少数患者纳入乳腺癌临床试验：临床试验环境的作用

Inclusion bias of patients with genetically different glioblastoma subgroups in clinical trials

著录项

相似文献

相关主题

期刊订阅